Novocure sees FY26 revenue $675M-$705M, consensus $681.24M

Sees FY26 adjusted EBITDA loss of $20M to flat. The company said, “This guidance assumes full-year low-to-mid single digit net revenue growth from Optune Gio, net revenue contribution from Optune Lua and Optune Pax, collectively, between $15 million to $25 million, mid-70’s percent gross margin, and foreign exchange rates as of December 31, 2025.”